Clinical trials · Connecticut
Advanced or Metastatic Solid Tumors clinical trials in Connecticut
We’re tracking 211 recruiting advanced or metastatic solid tumors studies with a site in Connecticut — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Connecticut
- NCT04929223RecruitingPhase 1
Targeted drug study for metastatic colon or rectal cancer
This Phase 1 study tests targeted cancer treatments in people with metastatic colorectal cancer, using genetic “biomarker” results to match you to the right treatment group. It focuses first on safety, and also looks for early signs the treatment may work in specific tumor subgroups.
New Haven, ConnecticutAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Hartford, ConnecticutAges 18 years+ - NCT05280314RecruitingPhase 2
Immunotherapy before and after surgery for stage III melanoma or throat cancer
This trial tests two immunotherapy medicines given before surgery and again after surgery to help control the cancer and improve outcomes. It studies people with resectable (operable) stage III melanoma or certain stage III/IVA throat cancers.
New Haven, ConnecticutAges 18 years+ - NCT07817875RecruitingPhase 3
Tirzepatide for weight loss in children aged 6 to under 12
This study tests a once-weekly medication called tirzepatide to help children aged 6 to under 12 with obesity lose weight. It compares the medication to a placebo (inactive shot) to see if it safely helps with weight loss in this age group.
New Haven, ConnecticutAges 6–11 - NCT07758816Recruiting
Better treatments for Gaucher disease with lung or bone problems
This study looks at how standard treatments for Gaucher disease affect lung problems, bone damage, and parkinson-like symptoms. It aims to find better ways to treat these complications and improve quality of life.
New Haven, ConnecticutAges 3 months–75 years - NCT07700979RecruitingPhase 3
Testing a new drug combo for stomach cancer
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
New Haven, ConnecticutAges 18 years+ - NCT07578116RecruitingPhase 3
Adding surgery and radiation for her2-positive breast cancer with a few spread spots
This trial tests whether adding surgery and radiation to the usual HER2-targeted treatment helps people with breast cancer that has spread to a few spots. You must have HER2-positive cancer that is newly spread, and you must be able to receive radiation to all tumor sites.
Derby, ConnecticutAges 18 years+ - NCT07578571RecruitingPhase 1
Testing a New Cancer Treatment Called IM-1617
This is an early-stage study testing a new drug (IM-1617) for advanced solid cancers that have not responded to standard treatments. The drug combines an antibody with a cancer-killing agent and may help people whose cancer has progressed despite prior therapy.
New Haven, ConnecticutAges 18 years+ - NCT07426822RecruitingPhase 2
Preventing Rash and Diarrhea with Capivasertib for Breast Cancer
This trial tests whether giving a combination of the drugs capivasertib and fulvestrant, along with medicines to prevent rash and diarrhea, can help treat hormone receptor-positive breast cancer that has a PIK3CA, AKT1, or PTEN change. It's for people whose cancer has spread or is locally advanced and can't be removed with surgery.
New Haven, ConnecticutAges 18 years+ - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07215910RecruitingPhase 3
Testing vorasidenib with temozolomide after radiation for advanced brain cancer
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
New Haven, ConnecticutAges 12 years+ - NCT07198074RecruitingPhase 3
Testing Avastin added to chemo plus Keytruda for certain endometrial cancer
This study tests adding Avastin (bevacizumab) to the standard combination of chemotherapy (carboplatin and paclitaxel) plus immunotherapy (Keytruda) for advanced or recurrent endometrial cancer with a specific genetic makeup (pMMR and TP53 mutation). The goal is to see if adding Avastin helps shrink tumors or slow their growth.
Hartford, ConnecticutAges 18 years+ - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Farmington, ConnecticutAges 18 years+ - NCT07142304Recruiting
A study of compression gloves and boots to prevent chemo nerve damage
This trial is testing a wearable device (gloves and boots) that applies gentle compression to your hands and feet during chemotherapy. It aims to prevent or reduce nerve damage (numbness, tingling, pain) that some chemotherapy drugs can cause.
Norwich, ConnecticutAges 18 years+ - NCT07111520RecruitingPhase 1/Phase 2
Combination treatment for advanced lung cancer
This trial tests two investigational drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or can't be cured with local treatment. The goal is to see if the combination is safe and might help shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT06963905RecruitingPhase 1/Phase 2
Testing a combination drug for triple-negative breast cancer
This trial is testing a combination of three drugs—sacituzumab govitecan, nivolumab, and relatlimab—for people with metastatic triple-negative breast cancer that has progressed after at least one prior therapy. You may qualify if you have this specific type of breast cancer and have received certain prior treatments.
New Haven, ConnecticutAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
New Haven, ConnecticutAges 18 years+ - NCT06750484RecruitingPhase 2
Testing trastuzumab deruxtecan in HER2-zero breast cancer
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT06743126RecruitingPhase 3
IMA203 vs standard treatment for advanced skin cancer
This trial tests a new cell therapy called IMA203 against standard treatments for people with advanced melanoma (a type of skin cancer) that has spread or can't be removed. It may be an option if you have already tried certain treatments and your cancer has a specific cell marker (HLA-A*02:01).
New Haven, ConnecticutAges 18 years+ - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
New Haven, ConnecticutAges 18 years+ - NCT06662162Recruiting
Microcurrent therapy for dry age-related macular degeneration
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
Manchester, ConnecticutAges 60 years+ - NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Bristol, ConnecticutAges 18 years+ - NCT06632977RecruitingPhase 2
Matching targeted treatments to your prostate cancer's genetics
This trial is testing whether matching your cancer's specific genetic changes to a targeted treatment can help control metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. You may receive a drug, a radioactive treatment, or a combination based on your tumor's molecular profile.
Stamford, ConnecticutAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Derby, ConnecticutAges 18 years+
Advanced or Metastatic Solid Tumors trials by city in Connecticut
Where these studies are running in Connecticut
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Yale University · 14 studies
- Smilow Cancer Hospital Care Center - Waterford · 3 studies
- Smilow Cancer Hospital Care Center-Trumbull · 3 studies
- Smilow Cancer Hospital Care Center - Guilford · 2 studies
- Smilow Cancer Hospital Care Center at Greenwich · 2 studies
- Smilow Cancer Hospital Care Center at Long Ridge · 2 studies
- Smilow Cancer Hospital Care Center at Saint Francis · 2 studies
- Smilow Cancer Hospital Care Center-Fairfield · 2 studies
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced or Metastatic Solid Tumors trials in other states
Common questions
- Are there advanced or metastatic solid tumors clinical trials in Connecticut?
- Yes. We're currently tracking 211 recruiting advanced or metastatic solid tumors studies with a site in Connecticut, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study in Connecticut?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Connecticut to take part?
- Not necessarily. These studies have a site in Connecticut, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open in Connecticut regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.